GlassScriptPhysician profile
Abby N Link
NPI 1821415233
$3,865.72
in general payments reported to CMS, 2019-2025
28 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.10 · 2023: $1,412 · 2024: $906 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.98 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $501.22 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $500.57 | 2023-2025 | |
| Pfizer INC. | $326.28 | 2022-2025 | |
| Novo Nordisk INC | $230.74 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $207.18 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $183.87 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.32 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Esperion Therapeutics, INC. | $173.73 | 2023-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $153.88 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.64 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $111.65 | 2023-2025 | Gemtesa |
| Amgen INC. | $79.54 | 2023-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $71.02 | 2023 | Veozah, Myrbetriq |
| Heartflow, INC. | $53.45 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.97 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $42.14 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.21 | 2025 | Caplyta |
| Ironwood Pharmaceuticals, INC | $39.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.84 | 2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $36.44 | 2023 | Livalo |
| Daiichi Sankyo INC. | $36.03 | 2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.52 | 2023 | Ibschek, Xifaxan |
| Axsome Therapeutics, INC. | $18.93 | 2025 | Auvelity |
| Exact Sciences Corporation | $18.72 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $17.50 | 2023 | |
| Ardelyx, INC. | $15.55 | 2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.